Abbvie
Whoa! How did you get here? This company profile is not meant to be publicly available. Research on this company is incomplete, and the overall rating has been disabled, but while you are here feel free to have a look at the info we do have.
OVERALL |
|
Owned |
USA |
Rating |
N/A |
Biopharmaceuticals
Abbvie Inc | USA | website |
Company Assessment
PRAISE | CRITICISM | INFORMATION | ||
Abbvie Inc | ||||
This company received an S&P Global ESG Score of 81/100 in the Biotechnology category of the S&P Global Corporate Sustainability Assessment, an annual evaluation of companies' sustainability practices (last updated 23 Sep 2022). The rankings are based on an analysis of corporate economic, environmental and social performance, assessing issues such as corporate governance, risk management, environmental reporting, climate strategy, human rights and labour practices.
Source: S&P Global (2022)
In 2023, the Carbon Disclosure Project (CDP) asked companies to provide data about their efforts to reduce greenhouse gas emissions and mitigate climate change risk. Responding companies are scored across four key areas: disclosure; awareness; management; and leadership. This company received a CDP Climate Change score of B.
Source: CDP (2023)
This company is listed as having best practice on a report card on lesbian, gay, bisexual and transgender equality in corporate America.
Source: Human Rights Campaign (2021)
In 2023, the Carbon Disclosure Project (CDP) asked companies to provide data about their efforts to manage and govern freshwater resources. Responding companies are scored on six key metrics: transparency; governance & strategy; measuring & monitoring; risk assessment; targets & goals; and value chain engagement. This company received a CDP Water Security score of B.
Source: CDP (2023)
JUST Capital polls Americans every year to identify the issues that matter most in defining just business behaviour. For their 2024 rankings the public identified 20 issues, which are organised under the headings Workers, Communities, Customers, Shareholders and Environment. JUST Capital then define metrics that map to those issues and track and analyse the largest, publicly traded U.S. companies. This analysis powers their rankings, in which this company ranked 250th of 937 companies, and 16th of 41 Pharmaceuticals & Biotech companies.
Source: JUST Capital (2024) |
This company received the second lowest score in the Access to Medicine Index 2022, a ranking of the world's 20 largest pharmaceutical companies on their efforts to increase access to medicine in developing countries. The ranking is based on their scores in each Technical Area, with Product Delivery weighted most highly, followed by R&D and Governance of Access.
Source: Access to Medicine Foundation (2022)
In June 2018, the US District Court ruled that this company used sham litigation to illegally maintain its monopoly over the testosterone replacement drug Androgel, and ordered US$448m in monetary relief to consumers who were overcharged for Androgel as a result of AbbVie's conduct.
Source: US Federal Trade Commission (2018)
The Green Supply Chain Corporate Information Transparency Index (CITI) evaluates consumer-facing companies that have a sizeable supply chain in China. The evaluation uses government supervision data and public information to assess the environmental management of their supply chains in China. This company received a score of 11.26/100 (retrieved 24 Nov 2023).
Source: IPE (2023)
In 2018 Abbott Laboratories and AbbVie Inc agreed to pay $25 million to resolve allegations that they employed kickbacks and unlawful methods of marketing and promotion to induce physicians to prescribe the drug TriCor. The settlement also resolved allegations that Abbott engaged in unlawful methods of off-label marketing and promotion relating to the sale of TriCor for unapproved indications.
Source: US Dept of Justice (2018)
In 2019 several pharmaceutical companies finally settled a 2005 lawsuit which claimed the companies fudged wholesale drug prices to increase Medicaid reimbursements. In all, the state of Illinois received a combined $648 million over the course of that litigation. A subsidiary of this company was involved in the 2019 settlement.
Source: news article (2019)
In 2020 this company, maker of the drug Humira, agreed to pay US$24m to settle a Californian lawsuit that alleged violations of insurance law. The lawsuit alleged that AbbVie unlawfully provided perks such as meals and drinks to California doctors to convince them to prescribe Humira and used registered nurses as "ambassadors" to patients - ostensibly to provide support for patient care - without disclosing they were working for the company
Source: Washington Post (2020)
The 2022 Nature Benchmark ranks 400 companies across eight industries on their efforts to protect our environment and its biodiversity. The companies were assessed using three measurement areas: governance and strategy; social inclusion and community impact; and ecosystems and biodiversity. This company ranked #188/400, with a total score of 15.2/100.
Source: World Benchmarking Alliance (2022) |
This company received a score of 26.5/100 in the Newsweek Green Ranking 2017, which ranks the world's largest publicly traded companies on eight indicators covering energy, greenhouse gases, water, waste, fines and penalties, linking executive pay to sustainability targets, board-level committee oversight of environmental issues and third-party audits. Ranking methodology by Corporate Knights and HIP Investor.
Source: Newsweek (2017)
In 2022 the median pay for a worker at this company was US$117,189. The CEO was paid 224 times this amount. Exorbitant CEO pay is a major contributor to rising inequality. CEOs are getting more because of their power to set pay, not because they are increasing productivity or possess specific, high-demand skills. The economy would suffer no harm if CEOs were paid less (or taxed more). In contrast, the CEO-to-typical-worker compensation ratio was 20-to-1 in 1965 and 58-to-1 in 1989.
Source: AFL-CIO (2023)
As You Sow's 2023 report, 'The 100 Most Overpaid CEOs', reveals the 100 most overpaid CEOs from USA's 500 largest public companies (as determined by the S&P 500 list). This company's CEO, Richard A. Gonzalez came in at number 89 on the list, having been paid US$23,912,154 in 2022. According to the report, "Most CEOs have come to be grossly overpaid, and that overpayment is harmful to the companies, the shareholders, the customers, the other employees, the economy, and society as a whole."
Source: As You Sow (2023)
As listed on the We Mean Business website, this company has committed to the following climate action initiatives: adopt a science-based emissions reduction target.
Source: We Mean Business (2021)
This company was named in the top 10 of Seramount's 100 Best Companies 2022 for being a mum-friendly employer. Listed companies provide inclusive benefits for families, including paid gender-neutral parental leave, phase-back programs, bereavement leave after miscarriage, reimbursement for fertility expenses, and increased mental health benefits for employees.
Source: Seramount (2022) |
Company Details
Type | Public company |
Founded | 2013 |
Subsidiaries | Allergan plc
Pharmaceuticals Irish-tax registered pharmaceutical company which generates most of its income from the US healthcare system. Formerly Actavis. Acquired Forest Laboratories in 2014, and Allergan Inc in 2015. Sold its generics business to Teva in 2016. Acquired by Abbvie in 2019. - Forest Laboratories Inc Pharmaceuticals Acquired by Actavis (now Allergan) in 2014 for US$28 billion. |
Contact Details
Address | Lake Bluff, Illinois, USA |
customerservice@abbvie.com | |
Website | abbvie.com |